- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00887926
Study of IMC-EB10 in Participant With Leukemia
December 20, 2022 updated by: Eli Lilly and Company
An Open-label, Dose Escalation, Phase I Study of IMC-EB10 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.
Study Overview
Detailed Description
The purpose of this study is to define the maximum tolerated dose (MTD) and the pharmacokinetic (PK) profile of the anti-FMS-like tyrosine kinase 3 (FLT3) monoclonal antibody IMC-EB10, administered weekly in participant with acute lymphoblastic leukemia (AML) who have failed to achieve complete remission to a standard induction regimen, relapsed after response to previous antileukemia therapy, or are not eligible for potentially curative or approved salvage options.
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- ImClone Investigational Site
-
-
Texas
-
Houston, Texas, United States, 77030
- ImClone Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The participant has acute myeloid leukemia in the bone marrow or blood that has relapsed with or without a prior complete remission
- The participant is not regarded to be a candidate for a potentially curative, higher priority treatment for acute myeloid leukemia
- The participant has resolution of all clinically significant toxic effects of any prior antitumor therapy and any other study-specific clinical or laboratory parameter specified in the entry criteria
- The participant has not had major surgery, an open biopsy, a significant injury, and/or prior antitumor therapy (except antileukemia therapy) within 21 days prior to the first infusion of IMC-EB10
- The participant has an Eastern Cooperative Oncology Group (ECOG)performance status of 0, 1, or 2 at study entry.
- The participant is age 18 years or older
- The participant has a life expectancy of >3 months
- The participant has adequate liver and kidney function, as defined in the entry criteria
- The participant is using an effective contraception (per the institutional standard), if procreative potential exists
- The participant is able to give written informed consent
- The participant is willing and able to comply with study procedures, scheduled visits, and treatment plans
Exclusion Criteria:
- The participant has had prior allogenic or autologous stem cell transplant within <3 months of the first infusion of IMC-EB10
- The participant has had an organ transplant (nonhematologic) within 3 years of study entry
- The participant has active central nervous system leukemia
- The participant has extramedullary disease without peripheral/and or bone marrow involvement
- The participant is disease-free from a previous or concurrent malignancy for a period ≤ 1 year. A participant who has basal cell carcinoma or carcinoma in situ of the cervix will not be excluded from the study
- The participant is currently receiving antileukemia therapy. Concurrent treatment with hydroxyurea is permitted
- The participant has uncontrolled intercurrent illness as specified in the study entry criteria
- The participant is receiving chronic steroid or other immunosuppressive medications. Occasional use of steroid-containing medications for, for example (e.g.), asthma exacerbation or for skin lesions, is permitted
- The participant is receiving full-dose heparin (including low molecular weight heparin) or warfarin. [The participant is permitted to use low-dose warfarin to maintain patency of preexisting, permanent, indwelling intravenous (I.V.) catheters.]
- The participant is pregnant (confirmed by urine or serum pregnancy test) or breast feeding
- The participant has received treatment with monoclonal antibodies within 6 weeks prior to first infusion of IMC-EB10
- The participant has a history of clinically significant allergic reactions to monoclonal antibodies or other therapeutic proteins
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IMC-EB10 5 milligrams/kilogram (mg/kg)
All participants will receive intravenous infusions of IMC-EB10, with the dose depending on which cohort they are enrolled into.
|
Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period.
The starting dose in Cohort 1 will be 5 mg/kg.
After all participants in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg.
Participants who experience a dose-limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol.
Participants may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received.
Dosing for Cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerate Dose (MTD) of IMC-EB10
Time Frame: Cycle 1 (28-day cycle)
|
MTD is defined as the dose preceding the dose level at which 2 participants experienced a dose limiting toxicity (DLT) during Cycle 1. DLT is defined using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v 3.0): (1) any Grade 3 or 4 toxicity that is clearly not attributable to leukemia [for example (e.g.) a type of end-organ failure that is infrequently encountered in acute myeloid leukemia (AML)] and is possibly, probably, or definitely attributable to IMC-EB10 in the judgment of the investigator; and (2) any Grade 3 or 4 toxicity that is clearly not attributable to a co-medication (e.g., prolonged neutropenia that is not attributable to hydroxyurea).
|
Cycle 1 (28-day cycle)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK): Maximum Concentration (Cmax)
Time Frame: Cycle 1 Week 1: predose, immediately after infusion, and 1.5, 2, 4, 8, 24, 96, and 168 h after infusion ends, and Cycle 1 Week 3: predose, immediately after infusion, and 1.5, 2, 4, 8, 24, 48, 96,168, 240 and 336 h after infusion ends (28-day cycles)
|
Cycle 1 Week 1: predose, immediately after infusion, and 1.5, 2, 4, 8, 24, 96, and 168 h after infusion ends, and Cycle 1 Week 3: predose, immediately after infusion, and 1.5, 2, 4, 8, 24, 48, 96,168, 240 and 336 h after infusion ends (28-day cycles)
|
|
PK: Area Under the Concentration Versus Time Curve From Time Zero to Last Measurable Concentration [AUC(0-last)]
Time Frame: Cycle 1 Week 1: predose, immediately after infusion, and at 1.5, 2, 4, 8, 24, 96 and 168 h after infusion ends (28-day cycle)
|
Cycle 1 Week 1: predose, immediately after infusion, and at 1.5, 2, 4, 8, 24, 96 and 168 h after infusion ends (28-day cycle)
|
|
PK: Area Under the Concentration Time Curve During the Dosing Interval (AUCtau) Where Tau is 168 Hours
Time Frame: Cycle 1 Week 3: predose, immediately after infusion and at 1.5, 2, 4, 8, 24, 48, 96,168, 240 and 336 h after infusion ends (28-day cycle)
|
Cycle 1 Week 3: predose, immediately after infusion and at 1.5, 2, 4, 8, 24, 48, 96,168, 240 and 336 h after infusion ends (28-day cycle)
|
|
Number of Participants With Adverse Events (AEs) (Safety Profile of IMC-EB10)
Time Frame: 8 weeks and 30-day post-treatment follow-up
|
Clinically significant events were defined as serious adverse events (SAEs) and other non-serious AEs regardless of causality.
A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module
|
8 weeks and 30-day post-treatment follow-up
|
Number of Participants With Anti-IMC-EB10 Antibodies
Time Frame: Cycle 1, Weeks 1 and 3 and Cycle 2, Week 1: predose (28-day cycles)
|
A participant is considered positive for antibodies against IMC-EB10 if their blood sample exhibited a post-treatment antibody level that exceeds the positive upper cut point determined from the anti-IMC-EB10 level in healthy untreated individuals.
A participant was considered to have an anti-IMC-EB10 response if there are 2 consecutive positive samples or if the final sample tested is positive.
|
Cycle 1, Weeks 1 and 3 and Cycle 2, Week 1: predose (28-day cycles)
|
Number of Participants With Antileukemic Complete Response (CR) or Partial Response (PR)
Time Frame: 4 weeks
|
Assessment of antileukemic response was based on hematologic response criteria.
PR defined as >1000/microliter (µL) neutrophils and ≥100000/µL platelets in peripheral blood; a decrease of ≥50% in the pretreatment percentage of blasts to 5% to 25% in the bone marrow aspirate or a value of ≤5% blasts if Auer rods are present.
Cytogenetic CR defined as normal cytogenetic findings.
Molecular CR defined as negative findings for minimal residual disease by automated quantitative Reverse-Transcription-Polymerase Chain Reaction (RT-PCR) and multidimensional flow cytometry.
Morphologic CR with incomplete blood count recovery defined as ≤5% blasts (containing no Auer rods) in a bone marrow aspirate with spicules; neutrophil count < 1000/µL or platelets <100000/mL in peripheral blood or no extramedullary leukemia present.
|
4 weeks
|
Number of Participants With Feline McDonough Sarcoma (FMS)-Like Tyrosine Kinase 3 (FLT3) Response
Time Frame: Week 4 and Week 8
|
FLT3 response to IMC-EB10 is defined as wild type, internal tandem duplications (ITD) mutations and other mutations.
|
Week 4 and Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: E-mail: ClinicalTrials@ ImClone.com, Eli Lilly and Company
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
August 1, 2010
Study Completion (Actual)
August 1, 2010
Study Registration Dates
First Submitted
April 23, 2009
First Submitted That Met QC Criteria
April 23, 2009
First Posted (Estimate)
April 24, 2009
Study Record Updates
Last Update Posted (Actual)
December 22, 2022
Last Update Submitted That Met QC Criteria
December 20, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13959
- CP17-0801 (Other Identifier: ImClone, LLC)
- I5C-IE-JEBA (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Peking University People's HospitalBeijing JD Biotech Co. LTD.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Bio-Path Holdings, Inc.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Yale UniversityPfizerTerminatedACUTE MYELOID LEUKEMIAUnited States
-
Xuzhou Medical UniversityRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
Clinical Trials on IMC-EB10
-
Eli Lilly and CompanyCompletedMalignant MelanomaUnited States
-
ImmuneOncia Therapeutics Inc.RecruitingAdvanced CancerKorea, Republic of
-
ImmuneOncia Therapeutics Inc.Not yet recruitingA Study of Phase2, IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (TMB-H)TMB-H | Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
-
Innovative Med Concepts, LLCCompletedChronic Pain | Fibromyalgia | Myofascial PainUnited States
-
ImmuneOncia Therapeutics Inc.CompletedLymphoma | Solid TumorKorea, Republic of, United States
-
Eli Lilly and CompanyCompletedNeoplasms | Neoplasm MetastasisUnited States
-
Immunocore LtdRecruitingSelect Advanced Solid TumorsUnited States, Belgium, Korea, Republic of, Australia, Germany, United Kingdom, Spain, Poland, Austria, Brazil, Canada, New Zealand, France, Italy, Netherlands, Switzerland
-
CorAssist Cadiovascular Ltd.TerminatedHeart Failure With Normal Ejection Fraction
-
ImmuneOncia Therapeutics Inc.Active, not recruitingA Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal TypeExtranodal NK/T-cell Lymphoma, Nasal Type | Extranodal NK/T-cell LymphomaKorea, Republic of
-
Virios Therapeutics, Inc.CompletedFibromyalgiaUnited States